Nurzen SEZGİN, Murat GÜLŞEN, Tolga YAKAR, Hakan SAKALLI, Mustafa GÜÇLÜ

Evaluation of serum lipid profile in Turkish patients with chronic hepatitis C

Amaç: Bu çalışmada kronik kronik hepatit C virus (HCV) enfeksiyonunun serum lipid profili üzerine etkisini araştırdık. Metod: Karaciğer biyopsisi ile kronik hepatit C tanısı alan ve herhangi bir tedaviye başlanmamış 17 kadın 11 erkek 28 hasta (yaş ortalaması:58,2±7,9 yıl) ile 22 kadın 11 erkek sağlıklı 33 kişi (yaş ortalaması:51,1±7,4 yıl) çalışmaya alındı. Karaciğer biyopsi örnekleri Knodell’in histoloji aktivite indeksine göre değerlendirildi. Hasta ve kontrol grubunda bir kez olmak üzere serumda Albumin, trombosit, total kolesterol, ApolipoproteinA1, ApolipoproteinA2, ApolipoproteinB, ApolipoproteinE, total lipid ve diğer biyokimyasal parametreler ölçüldü. Bulgular: Kronik hepatit C’li hastalar da kontrol grubu ile karşılaştırıldığında sırasıyla alanine aminotransferase (104±11 ve 21±11) IU/L, aspartat aminotransferase (74±5 ve 19±7) IU/L ve apolipoprotein A1 (137,68±38,46 ve 119,27±19,84) mg/dl değerleri her biri için anlamlı derecede yüksek iken (p

Kronik hepatit C’li Türk hastalarda serum lipid profilinin değerlendirilmesi

Aim: In this study we researched the effect of chronic hepatitis C virus (HCV) infection on serum lipid profile. Method: 28 patients (age average: 58.2±7.9 years) 17 of them women and 11 of them men and 33 healthy people (age average: 51.1±7.4 years) 22 of them women and 11 of them men taking chronic hepatitis C diagnosis through liver biopsy and in that any treatment wasn’t started yet were taken into the study. Liver biopsy samples were evaluated according to Knodell’s histology activity index. As once in the patient and control group, Albumin, platelet, total cholesterol, Apolipoprotein A1, Apolipoprotein A2, Apolipoprotein B, Apolipoprotein E, total lipid and other biochemical parameters were measured in the serum. Result: In patients with chronic hepatitis C, when compared with the control group, while alanine aminotransferase (104±11 and 21±11) IU/L, aspartat aminotransferase (74±5 and 19±7) IU/L and apolipoprotein A1 (137.68±38.46 and 119.27±19.84) mg/dl values were meaningfully high for each one (p

PDF

___

1. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992;15:572-7.
2. Lfkowitch JH, Schiff ER, Davis GL, et al. Pathological diagnosis of chranic hepatitis C: a multicenter camparative study with chronic hepatitis B. Gasroenterology 1993; 104:595-603.
3. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of chranic hepatitis C. Hepatology 1992;15:567-71.
4. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cellsvia low-density lipoprotein receptor. Proc Natl Acad Sei USA 1996;96:12766-71.
5. Monazahian M, Bohme 1, Bonk S, et al. Low densty lipoprotein receptor as a candidate receptorfor hepatitis C virus. J Med Virol 1999;57:223-9.
6. Barba G, Harper F, Harada T, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to collular lipid storage droplet. Proc Natl Acad Sci USA 1997;94:1200-5.
7. Sabila A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein Aıı and its secretion is modulated by fibrates. Hepatolgy 1999;30:1064-76.
8. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatiits C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis. J Hepatol 2001;34:428-34.
9. Kyoji Moriya et all. Serum lipid profilo of patients with genotype 1b hepatitis C viral infection in Japan. Hepatology Research 2003; 25: 371-76.
10. Parlemuter G, Sabila A, Letteron P, et al. Hepatitis C virus core protein inhibits triglyceride-transfer protein activity and very low-density lipoprotein secration: amodel of viral-related steatosis. FASEB J 2002;16:185-94.
11. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Steals B. Negative regulation of the human apolipoprotein A-1 promoter by fibrates can be atteunated by the interaction of the proxisome proliferator-activated receptor with its response element. J Biol Chem 1994; 269:31012-8.
12. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the proxisome proliferator-activated receptor. J Clin Insevt 1995;96:741-50.
13. Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection : Prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190-5.
14. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis ia a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15.
15. Kumar D, Farrel GC, Fung C, et al. Hematitis C virus genotype 3 is cytopathic to hepatocytes.Genotype specific reversal of hepatic steatosis after sustained response to antiviral therapy. Hepatology 2002;36:1266-72.
16. Poynard T, Ratziu V, McHutchison J. et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38:75-85.
17. Adinolfi LE, Gambardella A, Tripodi MF, Utili R, Ruggiero G, Andreana A. Steatosis accelerates the progession of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
18. Lagging LM, Garcia CE, Westin J, et al. Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen stroge time. J Clin Microbiol 2002;40:4224-9.
19. Bressler BL, Guindi M, Tomlinson G, Heatcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639-44.
20. Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: Can weight reduction improve therapeutic efficacy. J Hepetol 2001;35:432-3.